Latest News and Press Releases

LONDON, April 4, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces today that it intends to list its shares on NASDAQ. As an interim step, the Company will establish a Level...

LONDON and EDMONTON, Alberta, Canada, March 14, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces that it has signed an agreement with Raylo Chemicals of Edmonton, Alberta,...

LONDON, March 10, 2005 (PRIMEZONE) -- Antisoma plc (LSE: ASM) today announces that Chief Executive Officer, Glyn Edwards, will be presenting at the 25th SG Cowen Annual Healthcare conference, Boston,...

LONDON, Feb. 16, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces its interim results for the period ended 31 December 2004. Highlights - Acquisition of U.S....

LOUISVILLE, Ken. and LONDON, Feb. 4, 2005 (PRIMEZONE) -- Further to the announcement made yesterday, Antisoma plc (LSE:ASM) announces the completion of its acquisition of Aptamera Inc. This follows...

LONDON and LOUISVILLE, Ken., Feb. 3, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces that the shareholders of Aptamera Inc yesterday approved Antisoma's acquisition of...

LOUISVILLE, Ken. and LONDON, Jan. 10, 2005 (PRIMEZONE) -- Acquisition will add promising clinical product AGRO100 to Antisoma's pipeline Cancer drug development company Antisoma plc (LSE:ASM)...

LONDON, Nov. 23, 2004 (PRIMEZONE) -- Speaking at today's Annual General Meeting of Antisoma plc (LSE:ASM), Chairman Dr. Barry Price will review progress in the Company's pipeline of cancer drugs and...

LONDON, Nov. 4, 2004 (PRIMEZONE) -- Cancer drug developer Antisoma today presents new data showing that one of its telomere targeting agents (TTAs) rapidly blocks prostate tumour growth in a human...

LONDON, Oct. 6, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) will today present further promising data for its targeted apoptosis drug AS1406. Speaking at the Human...